This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vascular Effects of Hesperidin in Metabolic Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by University of Rome Tor Vergata.
Recruitment status was:  Recruiting
Information provided by:
University of Rome Tor Vergata Identifier:
First received: June 3, 2009
Last updated: June 16, 2009
Last verified: June 2009
It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

Condition Intervention Phase
Endothelial Dysfunction Metabolic Syndrome Drug: Hesperidin Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome

Resource links provided by NLM:

Further study details as provided by University of Rome Tor Vergata:

Primary Outcome Measures:
  • Safety of oral supplementation of hesperidin [ Time Frame: 3 weeks ]

Secondary Outcome Measures:
  • Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers. [ Time Frame: 3 weeks ]

Estimated Enrollment: 30
Study Start Date: November 2008
Estimated Study Completion Date: December 2010
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Hesperidin, 500 mg per day
500 mg daily of oral Hesperidin for 3 weeks
Drug: Hesperidin
Administration of oral Hesperidin, 500 mg/daily
Placebo Comparator: Placebo Drug: Placebo
Administration of oral Placebo, 500 mg/daily


Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metabolic Syndrome (ATPIII criteria)
  • BMI <35
  • Age 20-55

Exclusion Criteria:

  • History of cancer.
  • History of cardiovascular diseases.
  • Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00914251

University of Rome Tor Vergata Recruiting
Rome, Italy, 00133
Contact: Stefano Rizza, MD   
Principal Investigator: Stefano Rizza, MD         
Sub-Investigator: Manfredi Tesauro, MD         
Sub-Investigator: Davide Lauro, MD         
Sponsors and Collaborators
University of Rome Tor Vergata
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Stefano Rizza, Medicine Internal Department Identifier: NCT00914251     History of Changes
Other Study ID Numbers: 073/09
Study First Received: June 3, 2009
Last Updated: June 16, 2009

Keywords provided by University of Rome Tor Vergata:
metabolic syndrome

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on September 19, 2017